Dyne Therapeutics, Inc. DYN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s stock-based comp?
- Dyne Therapeutics, Inc. (DYN) reported stock-based comp of $13.08M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Dyne Therapeutics, Inc.'s stock-based comp increased by 0.5% year-over-year, from $13.02M to $13.08M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s stock-based comp has grown at a 27.2% compound annual growth rate (CAGR), from $17.54M to $45.85M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.